SG11201400769PA - Quinolyl-containing Hydroxamic Acid Compound and Preparation Method Thereof, and Pharmaceutical Composition Containing This Compound and Use Thereof - Google Patents

Quinolyl-containing Hydroxamic Acid Compound and Preparation Method Thereof, and Pharmaceutical Composition Containing This Compound and Use Thereof

Info

Publication number
SG11201400769PA
SG11201400769PA SG11201400769PA SG11201400769PA SG11201400769PA SG 11201400769P A SG11201400769P A SG 11201400769PA SG 11201400769P A SG11201400769P A SG 11201400769PA SG 11201400769P A SG11201400769P A SG 11201400769PA SG 11201400769P A SG11201400769P A SG 11201400769PA
Authority
SG
Singapore
Prior art keywords
compound
quinolyl
preparation
pharmaceutical composition
hydroxamic acid
Prior art date
Application number
SG11201400769PA
Inventor
Ziwei Yun
Hongtao Wang
Original Assignee
Beijing Konruns Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Konruns Pharmaceutical Co Ltd filed Critical Beijing Konruns Pharmaceutical Co Ltd
Publication of SG11201400769PA publication Critical patent/SG11201400769PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
SG11201400769PA 2011-09-19 2011-09-27 Quinolyl-containing Hydroxamic Acid Compound and Preparation Method Thereof, and Pharmaceutical Composition Containing This Compound and Use Thereof SG11201400769PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201110278403.9A CN102408411B (en) 2011-09-19 2011-09-19 Hydroximic acid compound containing quinolyl and preparation method thereof, and drug composition containing the compound and use thereof
PCT/CN2011/080213 WO2013040801A1 (en) 2011-09-19 2011-09-27 Hydroxamic acid compound containing quinolyl and preparation method thereof, and pharmaceutical composition containing this compound and use thereof

Publications (1)

Publication Number Publication Date
SG11201400769PA true SG11201400769PA (en) 2014-07-30

Family

ID=45910798

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201400769PA SG11201400769PA (en) 2011-09-19 2011-09-27 Quinolyl-containing Hydroxamic Acid Compound and Preparation Method Thereof, and Pharmaceutical Composition Containing This Compound and Use Thereof

Country Status (13)

Country Link
US (1) US9186318B2 (en)
EP (1) EP2769976B8 (en)
JP (1) JP5795826B2 (en)
KR (1) KR101879908B1 (en)
CN (1) CN102408411B (en)
AU (1) AU2011377440B2 (en)
CA (1) CA2858033C (en)
HK (1) HK1171009A1 (en)
NZ (1) NZ623923A (en)
RU (1) RU2573633C2 (en)
SG (1) SG11201400769PA (en)
TW (1) TWI472513B (en)
WO (1) WO2013040801A1 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3205654T3 (en) 2010-05-20 2019-08-30 Array Biopharma, Inc. Macrocyclic compounds as trk kinase inhibitors
CN103748074B8 (en) * 2011-06-17 2016-09-14 南昌弘益药业有限公司 Aryloxy group quinoline derivatives and therapeutic use thereof
CA2871092C (en) 2012-04-23 2017-05-09 Nemaska Lithium Inc. Processes for preparing lithium hydroxide
WO2013177367A2 (en) 2012-05-23 2013-11-28 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
RS57299B1 (en) 2012-05-30 2018-08-31 Nemaska Lithium Inc Processes for preparing lithium carbonate
PT2971252T (en) 2013-03-15 2021-04-06 Nemaska Lithium Inc Processes for preparing lithium hydroxide
PE20160658A1 (en) 2013-10-11 2016-08-05 Alios Biopharma Inc SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
KR102614113B1 (en) 2013-10-23 2023-12-13 네마스카 리튬 인코포레이션 Processes for preparing lithium carbonate
WO2015119122A1 (en) * 2014-02-04 2015-08-13 アステラス製薬株式会社 Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient
ES2863453T3 (en) 2014-02-24 2021-10-11 Nemaska Lithium Inc Procedures for handling lithium-containing materials
WO2016183071A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Hetero-tricyclic compounds and their use for the treatment of cancer
KR20180041135A (en) 2015-07-16 2018-04-23 어레이 바이오파마 인크. A pyrazolo [1,5-a] pyridine compound substituted as a RET kinase inhibitor
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
UA123785C2 (en) 2016-03-28 2021-06-02 Інсайт Корпорейшн Pyrrolotriazine compounds as tam inhibitors
CN107778285A (en) * 2016-08-24 2018-03-09 南昌弘益药业有限公司 A kind of quinolines noval chemical compound
CA2940509A1 (en) 2016-08-26 2018-02-26 Nemaska Lithium Inc. Processes for treating aqueous compositions comprising lithium sulfate and sulfuric acid
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
SG11201903463PA (en) * 2016-10-18 2019-05-30 Beijing Konruns Pharmaceutical Co Ltd Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition of the same, and use of the same
CN108329298A (en) * 2017-01-17 2018-07-27 南昌弘益药业有限公司 A kind of quinolines noval chemical compound preparation method
CN110267960B (en) 2017-01-18 2022-04-26 阿雷生物药品公司 Substituted pyrazolo [1,5-a ] pyrazine compounds as RET kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
CN108623565A (en) * 2017-03-23 2018-10-09 南昌弘益药业有限公司 A kind of preparation method of compound
JP6934261B2 (en) * 2017-05-24 2021-09-15 アビスコ セラピューティクス カンパニー リミテッド N- (azaaryl) cyclolactam-1-carboxamide derivative, its production method and application
JP2020535168A (en) 2017-09-27 2020-12-03 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Salts of pyrorotriazine derivatives useful as TAM inhibitors
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
TWI812649B (en) 2017-10-10 2023-08-21 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
WO2019100159A1 (en) 2017-11-22 2019-05-31 Nemaska Lithium Inc. Processes for preparing hydroxides and oxides of various metals and derivatives thereof
CN109836381A (en) * 2017-11-29 2019-06-04 连云港恒运药业有限公司 The preparation method of polyceptor tyrosine kinase inhibitor and its intermediate
CA3087354C (en) 2018-01-18 2023-01-03 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
JP7061195B2 (en) 2018-01-18 2022-04-27 アレイ バイオファーマ インコーポレイテッド Substituted pyrazolo [3,4-d] pyrimidine compound as a RET kinase inhibitor
JP6997876B2 (en) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Substituted pyrazolyl [4,3-C] pyridine compound as a RET kinase inhibitor
CA3088127A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
PE20211203A1 (en) 2018-01-26 2021-07-05 Exelixis Inc COMPOUNDS FOR THE TREATMENT OF KINE-DEPENDENT DISORDERS
EP3743417A1 (en) 2018-01-26 2020-12-02 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
US11535607B2 (en) 2018-04-20 2022-12-27 Valo Health, Inc. Isoindolines as HDAC inhibitors
EP3813800A1 (en) 2018-06-29 2021-05-05 Incyte Corporation Formulations of an axl/mer inhibitor
ES2922314T3 (en) 2018-09-10 2022-09-13 Array Biopharma Inc Fused Heterocyclic Compounds as RET Kinase Inhibitors
JP2022518506A (en) * 2019-01-25 2022-03-15 エグゼリクシス， インコーポレイテッド Compounds for the treatment of kinase-dependent disorders
MX2021012124A (en) * 2019-04-03 2021-12-10 Primegene Beijing Co Ltd Quinolyl-containing compound and pharmaceutical composition, and use thereof.
CN111825609A (en) * 2019-04-22 2020-10-27 北京康辰药业股份有限公司 Compound crystal form, preparation method, pharmaceutical composition and application thereof
CN114222588A (en) 2019-08-12 2022-03-22 雷杰纳荣制药公司 Macrophage stimulating 1 receptor (MST1R) variants and uses thereof
CN113116894A (en) * 2019-12-30 2021-07-16 北京康辰药业股份有限公司 Antitumor pharmaceutical composition and method for improving solubility of compound
CN113620873B (en) * 2020-05-07 2023-12-08 沈阳药科大学 Preparation method and application of zinc-containing binding group and quinoline skeleton compound

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU9502843D0 (en) * 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
EA199900139A1 (en) * 1996-08-23 1999-08-26 Пфайзер, Инк. DERIVATIVES OF ARYL SULPHONYLAMINO HYDROXAMIC ACID
DK1382604T3 (en) * 2001-04-27 2006-04-18 Kirin Brewery Quinoline derivatives with an azolyl group and quinazoline derivatives
US7495104B2 (en) 2001-10-17 2009-02-24 Kirin Beer Kabushiki Kaisha Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors
CN1187332C (en) * 2002-04-26 2005-02-02 中国科学院上海有机化学研究所 Tetrahydroisoquinoline hydroximic acid sulfamide compound, its synthesis method and its application
EP1566379A4 (en) 2002-10-29 2005-11-09 Kirin Brewery QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
US7199134B2 (en) * 2003-04-01 2007-04-03 Sloan-Kettering Institute For Cancer Research Hydroxamic acid compounds and methods of use thereof
EP2213661B1 (en) * 2003-09-26 2011-07-20 Exelixis Inc. c-Met Modulators and Methods of Use
US20080004273A1 (en) 2006-05-30 2008-01-03 Stephane Raeppel Inhibitors of protein tyrosine kinase activity
CA2663147A1 (en) * 2006-09-11 2008-03-20 Curis, Inc. Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety
JP2010502743A (en) * 2006-09-11 2010-01-28 キュリス，インコーポレイテッド Multifunctional small molecules as antiproliferative drugs
JP5580592B2 (en) * 2006-09-11 2014-08-27 キュリス，インコーポレイテッド Quinazoline-based EGFR inhibitors containing zinc binding moieties
WO2008033746A2 (en) * 2006-09-11 2008-03-20 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
US7999006B2 (en) 2006-12-14 2011-08-16 Exelixis, Inc. Methods of using MEK inhibitors
AU2007349284B2 (en) * 2007-03-20 2012-10-04 Curis, Inc. Raf kinase inhibitors containing a zinc binding moiety
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
EP2532657B9 (en) * 2008-10-14 2017-04-19 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
WO2010111063A1 (en) * 2009-03-21 2010-09-30 Ning Xi Amino ester derivatives, salts thereof and methods of use
UA108618C2 (en) * 2009-08-07 2015-05-25 APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
CN102086211B (en) * 2009-12-08 2013-09-11 广东东阳光药业有限公司 Aromatic heterocyclic compounds serving as protein kinase inhibitor
GB201111705D0 (en) * 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use

Also Published As

Publication number Publication date
KR101879908B1 (en) 2018-07-18
TW201313683A (en) 2013-04-01
EP2769976A1 (en) 2014-08-27
US20140221425A1 (en) 2014-08-07
JP2014526522A (en) 2014-10-06
RU2573633C2 (en) 2016-01-27
EP2769976B1 (en) 2017-08-02
RU2014112345A (en) 2015-10-27
US9186318B2 (en) 2015-11-17
TWI472513B (en) 2015-02-11
CN102408411A (en) 2012-04-11
KR20140069188A (en) 2014-06-09
CA2858033A1 (en) 2013-03-28
AU2011377440B2 (en) 2017-01-05
NZ623923A (en) 2015-05-29
WO2013040801A1 (en) 2013-03-28
JP5795826B2 (en) 2015-10-14
EP2769976A4 (en) 2015-06-03
EP2769976B8 (en) 2017-12-13
HK1171009A1 (en) 2013-03-15
CA2858033C (en) 2016-01-12
AU2011377440A1 (en) 2014-05-15
CN102408411B (en) 2014-10-22

Similar Documents

Publication Publication Date Title
SG11201400769PA (en) Quinolyl-containing Hydroxamic Acid Compound and Preparation Method Thereof, and Pharmaceutical Composition Containing This Compound and Use Thereof
LT2773335T (en) Oxalic acid amides as neprilysin inhibitors, pharmaceutical composition thereof and preparation thereof
IL233200A0 (en) Alpha-amino boronic acid derivatives, their preparation and pharmaceutical compositions containing them
HK1246674A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
IL231271A0 (en) Kynurenine-3- monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
IL258357A (en) Semisolid aqueous pharmaceutical composition containing tapentadol
IL230463A (en) Benzamides, their preparation and pharmaceutical compositions containing them
EP2702054A4 (en) Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use
EP2924042A4 (en) Bis- -carboline compound and preparation method, pharmaceutical composition and use thereof
EP2786982A4 (en) Amino-propylene-glycol derivatives, preparation method and pharmaceutical composition and use thereof
EP2692777A4 (en) Pharmaceutical composition containing block copolymer comprising boric acid compound
EP2781512A4 (en) Oxadiazole compound and preparation method thereof, pharmaceutical composition and use thereof
EP2738159A4 (en) Mercapto-benzophenone compounds, compositions and preparation methods thereof
EP2759547A4 (en) Platinum compound having amino- or alkylamino-containing succinic acid derivatives as leaving group, preparation method therefor, and use thereof
EP2704570A4 (en) Drug substances, pharmeceutical compositions and methods for preparing the same
IL230907A0 (en) Salt and polymorph of pyrazolopyrimidinone compound, and pharmaceutical composition containing the same, preparation method and use thereof
EP2766369A4 (en) Novel salts of sitagliptin, process for the preparation and pharmaceutical composition thereof
AP2013006793A0 (en) New dihydrobenzoxathiazepine compounds, a process for ther preparation and pharmaceutical compositions containing them
EP2565180A4 (en) Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same
SI2497774T1 (en) Dihydro-oxazolobenzodiazepinone derivatives, processes for their preparation and pharmaceutical compositions comprising these compounds
PL2736496T3 (en) Pharmaceutical composition containing an antimuscarinic agent and method for the preparation thereof
HK1250664A1 (en) Semisolid aqueous pharmaceutical composition containing tapentadol
EP2781521A4 (en) Novel spiroindoline compound, and medicinal agent comprising same
SI2819654T1 (en) Method for the preparation of a pharmaceutical composition comprising modafinil, composition obtained by this method and its application
ZA201105460B (en) Pharmaceutical composition comprising an isoxazole antireumatic agent and method for the preparation thereof